RAMACHANDRAN, RAVI K,HARDING, MATTHEW W,CARON, PAUL R,BOTFIELD, MARTYN,HARE, BRIAN J,BANDARU, RAJ,KELLIHER, KEVIN M,CORNELL, CATHARINE N
申请号：
NZ57305207
公开号：
NZ573052A
申请日:
2007.04.25
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is a method of evaluating a subject, the method comprising: determining the expression levels of the genes in a signature set of genes in the subject, wherein the signature set of genes comprises one or more interferon-sensitive genes(ISG) selected from the group consisting of IFIT1, RSAD2, IFIT2, IFIT6, IFI44, IFIT5, PLSCR1, IFIT3, IFI35, IFITM1, IFITM3, IFI30, IFITM2, GIP2, OAS3, MX1, IFIL44L, IFI27, IFIT2A, PRSAD, or IFITA, wherein the signature set has the following properties: it includes a plurality of genes each of which is differentially expressed as between virally infected individuals and non-infected individuals, and the differential expression is predictive of infection with no more than about 15% false positives and comparing the expression level of each of the genes in the set from the subject with a reference value, thereby evaluating the subject, wherein the reference value is either: (i) a non-infected reference and wherein differential expression of each of the genes in the signature set of genes indicates a first state, and differential expression of less than all of the genes in the signature set indicates a second state or (ii) an infected reference and wherein non-differential expression of each of the genes in the signature set of genes indicates a first state, and non-differential expression of less than all of the genes in the signature set indicates a second state, wherein the evaluating occurs prior to, during the course of, or after administering an inhibitor of a viral protease to the subject, and wherein the evaluation of the expression of the genes in a signature set of genes is performed on an isolated sample from the subject.
